TFF Pharmaceuticals, a clinical-stage biopharmaceutical company renowned for its Thin Film Freezing (TFF) technology platform, has selected Outcome Capital as its strategic advisor. The collaboration aims to evaluate and pursue potential corporate partnerships and licensing opportunities that leverage TFF Pharmaceuticals’ innovative drug products. Outcome Capital, a private equity firm recognized for its expertise in strategic advisory services, will play a crucial role in identifying and negotiating partnership deals to advance TFF Pharmaceuticals’ market reach and commercialization efforts.

Biopharmaceuticals, Private Equity,United States

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities